JP2022541344A5 - - Google Patents
Info
- Publication number
- JP2022541344A5 JP2022541344A5 JP2022505386A JP2022505386A JP2022541344A5 JP 2022541344 A5 JP2022541344 A5 JP 2022541344A5 JP 2022505386 A JP2022505386 A JP 2022505386A JP 2022505386 A JP2022505386 A JP 2022505386A JP 2022541344 A5 JP2022541344 A5 JP 2022541344A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cancer
- fragment
- therapy agent
- targeted therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902672A AU2019902672A0 (en) | 2019-07-26 | Methods of treatment | |
| AU2019902672 | 2019-07-26 | ||
| PCT/GB2020/051791 WO2021019222A1 (en) | 2019-07-26 | 2020-07-24 | P2x7 receptor targeted therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541344A JP2022541344A (ja) | 2022-09-22 |
| JP2022541344A5 true JP2022541344A5 (https=) | 2023-08-01 |
| JP7853205B2 JP7853205B2 (ja) | 2026-04-28 |
Family
ID=72039614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505386A Active JP7853205B2 (ja) | 2019-07-26 | 2020-07-24 | Ｐ２ｘ７受容体の標的療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220251187A1 (https=) |
| EP (1) | EP4003531A1 (https=) |
| JP (1) | JP7853205B2 (https=) |
| CN (1) | CN114173811A (https=) |
| AU (1) | AU2020319701A1 (https=) |
| BR (1) | BR112022000142A2 (https=) |
| CA (1) | CA3143419A1 (https=) |
| MX (1) | MX2021015593A (https=) |
| WO (1) | WO2021019222A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12121539B2 (en) | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| CN113759131B (zh) * | 2021-09-28 | 2024-10-29 | 嘉兴蔚康科技有限公司 | 一种靶标蛋白组合在检测视网膜黄斑病变中的应用 |
| CN117771376B (zh) * | 2024-02-26 | 2024-05-03 | 四川大学华西第二医院 | 一类化合物在注意缺陷与多动障碍中的应用及产品 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4384852B2 (ja) * | 2001-01-17 | 2009-12-16 | イントリート ピーティーワイ リミテッド | 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置 |
| CN100497386C (zh) | 2001-09-03 | 2009-06-10 | 因特里特有限公司 | 非功能性p2x7受体的抗体及其应用 |
| ES2619681T3 (es) * | 2007-09-14 | 2017-06-26 | Biosceptre (Aust) Pty Ltd | Novedosos epítopos P2X7 |
| US20110229411A1 (en) * | 2008-11-27 | 2011-09-22 | Institut Gustave Roussy | Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatment |
| EP2467404B1 (en) * | 2009-08-20 | 2015-09-30 | Biosceptre International Limited | Anti p2x7 receptor antibodies and fragments thereof |
| WO2011075789A1 (en) * | 2009-12-24 | 2011-06-30 | Biosceptre International Limited | Antibodies to non-functional oligomeric p2x7 receptors |
| MX349321B (es) * | 2011-07-01 | 2017-07-21 | Biosceptre (Aust) Pty Ltd | Terapia combinada. |
| US12121539B2 (en) | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| MX2019004410A (es) * | 2016-10-21 | 2019-09-26 | Biosceptre Uk Ltd | Particulas citotoxicas. |
-
2020
- 2020-07-24 CN CN202080053631.3A patent/CN114173811A/zh active Pending
- 2020-07-24 WO PCT/GB2020/051791 patent/WO2021019222A1/en not_active Ceased
- 2020-07-24 CA CA3143419A patent/CA3143419A1/en active Pending
- 2020-07-24 JP JP2022505386A patent/JP7853205B2/ja active Active
- 2020-07-24 EP EP20754010.5A patent/EP4003531A1/en active Pending
- 2020-07-24 MX MX2021015593A patent/MX2021015593A/es unknown
- 2020-07-24 BR BR112022000142A patent/BR112022000142A2/pt unknown
- 2020-07-24 US US17/618,849 patent/US20220251187A1/en active Pending
- 2020-07-24 AU AU2020319701A patent/AU2020319701A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Butti et al. | Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges | |
| Zhao et al. | The next generation of immunotherapies for lung cancers | |
| ES2749098T3 (es) | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico | |
| ES2779123T3 (es) | Nanobodies biespecíficos | |
| JP2022541344A5 (https=) | ||
| JP7717686B2 (ja) | キメラｃｄ３融合タンパク質と抗ｃｄ３ベースの二重特異性ｔ細胞活性化エレメントの複合発現 | |
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| CN117959417A (zh) | 嵌合抗原受体和pd-1抑制剂的组合疗法 | |
| JP2021502334A5 (https=) | ||
| TR201901507T4 (tr) | Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu. | |
| TW201702270A (zh) | 癌症組合療法 | |
| AU2022206035B2 (en) | Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof | |
| JP2019070056A (ja) | 固形がんの治療剤 | |
| TWI828626B (zh) | 併用包含溶血性鏈球菌之菌體的製劑的療法 | |
| JP2024516818A5 (https=) | ||
| JP2024071393A5 (https=) | ||
| CN114728000A (zh) | 治疗癌症的新型药物组合 | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| KR20230050349A (ko) | Axl 유인 수용체를 이용한 암의 진단 방법 | |
| Holla et al. | Her-2 gene, receptors and drug target: A systematic review | |
| CN114514037B (zh) | 用于癌症的组合治疗 | |
| Kiełbowski et al. | Immunotherapeutics and other anticancer agents in the management of advanced gastric cancer | |
| US20260069692A1 (en) | Modified t-cells for use in the treatment of gastroesophageal cancer | |
| Díaz et al. | Therapies based on inhibitors of the epidermal growth factor receptor: reaching for the future | |
| CN118103066A (zh) | 抗cd40抗体的应用 |